Dr David Bearss Discusses FDA and Safer Cancer Drugs
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart...
Breaking the Cycle of Inflammation in Parkinson’s Disease
By Jill Drachenberg -- BioSpace July 15, 2024 Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression. Preventing or reversing neuroinflammation could be the next clinical...
New Vision Research Continues to Impact Research Through Seed Funding.
Charleston, South Carolina, June 5, 2024 – John Kauwe Ph.D., a 2013 CCAD awardee shares how CCAD made a difference in his research career. Kauwe is the president of BYU-Hawaii and owner of Halia Therapeutics, a company that discovers and develops novel...
Pushing Boundaries to Revolutionize Chronic Inflammation Therapy
By Joe Petroziello -- Pharmaceutical Executive June 13, 2024 Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions. During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia...
Targeting Chronic Inflammation Via the Inflammasome – Dr. David Bearss
PODCAST: Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of chronic inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the...
Utah Founder 100 Honorees Named
Venture Capital Podcast has released their Founder 100 honoree list for Utah. It is a crowd-nominated, peer-voted list of the state's top founders in terms of their attractiveness to investors. The honorees and a large group of investors will meet this evening in a...
Utah executives’ top 10 business apps
By Brittny Goodsell -- Utah Business Magazine David Bearss, CEO of Halia Therapeutics, says his company uses Carta to manage multiple things in the chronic inflammation biotech industry. “Biotech companies are always in need of large capital raises to support the...
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt NLRP3 inflammasome assembly BY RICHARD GUY, BIOPHARMA ANALYSTMay 23, 2024 Halia has a new take on drugging the NLRP3 inflammasome that centers on exploiting RAB10 biology to control...
AI Versus Alzheimer’s
By Heather Bergerson -- Utah Business Magazine Utah-based companies Halia Therapeutics and Canary Speech are collaborating to revolutionize how Alzheimer's disease can be monitored and treated. https://bit.ly/3z2AhkH
Dr. David Bearss Joins Conversations Life Science Leaders Aren’t Having Podcast
Beyond Employee Engagement: Unpacking Performance in Life Sciences Leadership - Executive Roundtable April 1, 2024 In this insightful episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon hosts an invaluable Life Science Executive Roundtable. The...
Fighting Inflammation and Alzheimer’s – Dr. David Bearss on BioTech Nation podcast
March 20, 2024/28:57/E24012 In this episode of BioTech Nation, Dr. David Bearss, President, and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered...
Clinical Trials Arena: Halia Therapeutics begins trial of HT-6184 for pain management
The study will enroll up to 80 adults who are undergoing the surgical removal of two or more molar teeth for inflammatory and pain management. February 16, 2024 US-based biopharmaceutical company Halia Therapeutics has begun a Phase II clinical trial to...
BioWorld: Halia to use Canary Speech’s AI vocal biomarker platform to inform development of HT-4253 for Alzheimer’s
Halia Therapeutics Inc. and Canary Speech Inc. have established a collaboration in Alzheimer’s disease. This collaboration leverages Canary Speech’s artificial intelligence (AI) vocal biomarker platform, which utilizes advanced AI algorithms to analyze subtle changes...
BioWorld – Halia closes a $30M series C to develop inflammasome inhibitors
Lee LandenbergerJanuary 31, 2024 Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead...
WSJ: The Future of Biotech Venture Capital – Read what Dr. David Bearss has to say
Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024 'Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said...
Longevity.Technology – Waging War on Chronic Inflammation
January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from...
Jeff Burton – Halia Therapeutics CFO participates in BioSpace Roundtable
Alternative Funding Strategies to Discuss at JPM https://www.youtube.com/watch?v=c3PAvs5gwFE The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that...
Halia Therapeutics CEO David Bearss featured on Bioworld Podcast
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing...
Halia Therapeutics to test HT-6184 in MDS patients for first time
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early...
Utah Business: How David J. Bearss co-founded Halia Therapeutics
Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most reluctant entrepreneur. Halia Therapeutics is the sixth company I’ve started, but most of the time, I still think of myself as the guy who used...
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315